Scienture Holdings, Inc.
SCNXAnalyst Consensus
Price Target Trend
Rating Trend
Recent Price Targets
| Date | Firm | Analyst | Target | Price Then | Source |
|---|---|---|---|---|---|
| Oct 23, 2026 | Maxim Group | $6.00(+124%) | $2.68 | TheFly |
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| Maxim Group | maintain | Buy | Oct 23, 2026 |
Earnings History
Next report: Nov 11, 2026 · EPS est. $-1.57| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Aug 13, 2026 | $-1.75 | $-2.25 | $343.6K | $2.0M |
| May 11, 2026 | $-0.08 | $-5.75 | $56.3K | $401.0K |
| Mar 24, 2026 | $-1.76 | $-5.50 | -$168.7K | $486.4K |
| Nov 12, 2025 | $-0.19 | $-3.75 | $590.0K | $2.5M |
| Aug 11, 2025 | $-0.48 | $-3.75 | — | $2.2M |
| May 12, 2025 | $-0.33 | $-3.75 | $10.3K | $2.0M |
| Mar 26, 2025 | $-20.50 | $-3.75 | $53.1K | $2.5M |
| Jan 14, 2025 | $-33.50 | $-0.15 | $64.9K | $2.3M |
News
Scienture Holdings, Inc. (SCNX) Shareholder/Analyst Call Prepared Remarks Transcript
Preliminary Unaudited Third Quarter Revenue Increased 256% Sequentially to Approximately $1.22 Million, Supported by Continued Arbli ™ Growth and the Commercial Launch of REZENOPY ™
Continued Arbli ™ sales growth, combined with REZENOPY ™ commercial launch in August 2026 and initial wholesale shipments, drives significant sequential revenue growth
Major Institutional Formulary Win Expands Arbli ™ 's Presence in Pediatric Care as Wholesale Orders Continue to Increase Sequentially
COMMACK, NY, Sept. 30, 2026 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX) (“Scienture”), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through the development, commercialization, and distribution of novel specialty products that address unmet market needs, today announced that it has determined to effect a reverse stock split of its outstanding shares of common stock at a rati…
Agreement provides dedicated commercial channel for REZENOPY ™ across approximately 2,000 OTP (Opioid Treatment Program) Clinics and other Addiction Treatment Center Networks in the United States
Management to Highlight Growing Commercial Momentum of Arbli ™ and the Commercial Launch of REZENOPY ™
Q2 2026 Gross Margin Was Approximately 97.7%, Reflecting the Company's Growing Commercial Revenue Base Q2 2026 Operating Loss Improved Approximately 48% Year-over-Year to Approximately $2.7 Million Q2 2026 Net Loss Narrowed Approximately 58% Year-over-Year to Approximately $2.8 Million Commenced Commercial Launch of REZENOPY™, Establishing the Company's Second Commercial Product and Expanding Its Revenue-Generating Portfolio COMMACK, NY, Aug. 14, 2026 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC.…
Commercial launch supported by a dedicated national sales force, payer and institutional access, and multi-channel marketing campaign supporting adoption of REZENOPY ™